Boehringer Ingelheim

This study looked at the safety and effectiveness of Pradaxa oral pellets in children aged 3 months to 12 years who had blood clots (venous thromboembolism). The goal was to see how often bleeding or new clots occurred in real-world use. Only 5 children were enrolled before the s…

This study tested a single dose of an inhaled gene therapy called BI 3720931 in adults with cystic fibrosis who cannot use standard CFTR modulator drugs. The trial had two phases: first, different doses were tested for safety, then a placebo-controlled phase measured lung functio…

This study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…

This early-phase trial tested a new immunotherapy called BI 1821736 in 10 adults with advanced solid tumors that had not responded to standard treatments. BI 1821736 is a specially designed virus meant to kill cancer cells and help the immune system fight the cancer. Participants…

This study tested whether the drug Avenciguat, taken alone or with empagliflozin, could lower high blood pressure in the main liver vein in people with cirrhosis. The trial included 90 adults with cirrhosis caused by hepatitis or fatty liver disease. Participants took the drugs f…

This study tested a drug called BI 765845 in 160 adults who had just had a heart attack. Participants received either the drug or a placebo, and researchers measured heart damage using MRI scans. The trial was terminated early, so the full results are not available.

This study tested a medicine called Avenciguat for people with liver cirrhosis and high blood pressure in the portal vein (the main vessel to the liver). About 80 adults were randomly assigned to take different doses of Avenciguat or a placebo twice daily for 24 weeks. The goal w…

This study looks at the long-term safety and effectiveness of spesolimab for people with hidradenitis suppurativa (HS), a painful skin condition. Participants who completed a prior spesolimab study receive injections under the skin every 2 weeks for about 1.5 years. The goal is t…

This study tested a new cancer pill called BI 907828 in 99 adults with advanced bile duct, pancreas, lung, or bladder cancers that had stopped responding to other treatments. The drug works by blocking a protein called MDM2, which helps some cancers grow. Participants took the pi…

This study tested whether adding an experimental daily pill (BI 706321) to the standard Crohn's drug ustekinumab could better control moderate to severe Crohn's disease. About 49 adults took either the combo or a placebo plus ustekinumab for 3 months, then ustekinumab alone for 9…

This study looked at the long-term safety of a medicine called iclepertin in adults with schizophrenia who had already finished earlier studies. About 1,356 participants took iclepertin tablets once a day for one year, along with their usual schizophrenia medications. The main go…

This early-stage trial tested a new drug called BI 765883, given alone or with chemotherapy, for people with advanced pancreatic cancer that had spread or returned after surgery. The study aimed to find a safe dose and see if the drug could shrink tumors. Only 8 people took part …

This study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…

This study tested an experimental drug called BI 1839100 in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) who have a chronic cough. Participants took different doses of the drug or a placebo for 3 months. Researchers measured cough freque…

This was a very early (Phase 1) study to check the safety and how the body handles an experimental drug called BI 706321. It involved 48 healthy Japanese and Chinese men. The trial was terminated early, so results are limited.

This study was designed to observe how Netherton Syndrome (a rare genetic skin condition) progresses naturally in patients. Researchers planned to track symptoms like redness and scaling using standard severity scores. The study was terminated early and did not test any treatment…

This early-phase study tested a special PET imaging technique to see where an experimental drug (BI 754111) goes in the body and whether it reaches tumors. It involved 8 people with advanced non-small cell lung cancer or head and neck squamous cell carcinoma who also received ano…

This early-stage trial tested the safety and how the body processes a single dose of the experimental drug BI 1569912 in 68 healthy men. The study also looked at how food affects drug absorption. The trial was terminated, so results are limited.

This early-stage trial aimed to check the safety and how the body handles a new drug called BI 3731579. It involved 30 healthy adults who took multiple doses over 15 days. The study was terminated early, and no results are available. Since it only tested safety in healthy people,…

This early-stage study looked at how healthy men absorb, break down, and eliminate the experimental drug BI 1839100. The trial had two parts: one measured how much of the drug and its radioactive tracer was recovered in urine and stool after an oral dose, and the other compared d…

This early-stage trial tested the safety and how the body handles a new drug called BI 3009947 in 40 healthy men. The study was terminated early. It was not designed to treat any disease, but to gather basic information about the drug's safety and processing in the body.

This study looks at how healthy men absorb, break down, and eliminate the experimental drug BI 1819479. It involves taking the drug by mouth and, in one part, receiving a tiny radioactive tracer through a vein. The goal is purely to gather information, not to treat any disease. T…